Download PDF

1. Company Snapshot

1.a. Company Description

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States.It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML.In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors.


It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein.The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687.GlycoMimetics, Inc.


was incorporated in 2003 and is headquartered in Rockville, Maryland.

Show Full description

1.b. Last Insights on GLYC

GlycoMimetics, Inc.'s recent performance has been negatively impacted by the lack of significant updates on its pipeline, particularly its lead program, uproleselan, which has been in Phase 3 trials since 2020. The company's silence on this program has led to investor uncertainty. Meanwhile, competitor Crescent Biopharma's upcoming presentation at the TD Cowen 45th Annual Health Care Conference, highlighting its CR-001 bispecific antibody, may have drawn attention away from GlycoMimetics' own pipeline.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million

Jun -16

Source: globenewswire.com

Card image cap

GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals

Jun -05

Source: businesswire.com

Card image cap

Crescent Biopharma to Present at the Jefferies Global Healthcare Conference

May -29

Source: globenewswire.com

Card image cap

Crescent Biopharma Appoints David Lubner to Board of Directors

Apr -28

Source: globenewswire.com

Card image cap

Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics

Apr -03

Source: globenewswire.com

Card image cap

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders

Mar -05

Source: prnewswire.com

Card image cap

Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

Feb -26

Source: globenewswire.com

Card image cap

Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024

Nov -12

Source: prnewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (0.00%)

6. Segments

Glycomimetic Compounds

Expected Growth: 12.4%

Growing demand for targeted therapies, increasing prevalence of cancer and inflammatory disorders, and GlycoMimetics' innovative glycomimetic compounds driving market growth.

7. Detailed Products

Uproleselan

Uproleselan is a small molecule glycomimetic drug candidate that is designed to inhibit E-selectin, a type of adhesion molecule that plays a key role in the trafficking of cancer cells to the bone marrow, thereby reducing the risk of bone metastasis.

GMI-1271

GMI-1271 is a small molecule glycomimetic drug candidate that is designed to inhibit E-selectin, which is involved in the trafficking of cancer cells to the bone marrow, thereby reducing the risk of bone metastasis.

GMI-1359

GMI-1359 is a dual-function antagonist that is designed to inhibit both E-selectin and CXCR4, which are involved in the trafficking of cancer cells to the bone marrow, thereby reducing the risk of bone metastasis.

8. GlycoMimetics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

GlycoMimetics, Inc. has a moderate threat of substitutes due to the availability of alternative treatments for cancer and sickle cell disease. However, the company's focus on glycomimetics and its pipeline of novel compounds may provide a competitive advantage.

Bargaining Power Of Customers

GlycoMimetics, Inc. has a low bargaining power of customers due to the specialized nature of its products and the lack of alternative treatments for certain diseases. This gives the company pricing power and flexibility in its negotiations with customers.

Bargaining Power Of Suppliers

GlycoMimetics, Inc. has a moderate bargaining power of suppliers due to its reliance on a few key suppliers for raw materials and manufacturing services. However, the company's focus on glycomimetics and its pipeline of novel compounds may provide some negotiating power with suppliers.

Threat Of New Entrants

GlycoMimetics, Inc. has a high threat of new entrants due to the attractiveness of the biotechnology industry and the potential for new companies to enter the market with innovative products and technologies.

Intensity Of Rivalry

GlycoMimetics, Inc. operates in a highly competitive industry with several established players and a high level of rivalry. The company must differentiate itself through its products and services to maintain a competitive advantage.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 2.06%
Debt Cost 3.95%
Equity Weight 97.94%
Equity Cost 15.39%
WACC 15.15%
Leverage 2.10%

11. Quality Control: GlycoMimetics, Inc. passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Synlogic

A-Score: 4.8/10

Value: 7.2

Growth: 5.6

Quality: 4.8

Yield: 0.0

Momentum: 8.5

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
scPharma

A-Score: 4.8/10

Value: 8.2

Growth: 4.7

Quality: 4.5

Yield: 0.0

Momentum: 9.0

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Dyadic International

A-Score: 4.5/10

Value: 8.2

Growth: 5.0

Quality: 4.6

Yield: 0.0

Momentum: 8.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
GlycoMimetics

A-Score: 3.7/10

Value: 6.2

Growth: 4.6

Quality: 3.3

Yield: 0.0

Momentum: 6.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Mersana Therapeutics

A-Score: 3.4/10

Value: 9.2

Growth: 4.8

Quality: 5.8

Yield: 0.0

Momentum: 0.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Genelux

A-Score: 3.2/10

Value: 6.0

Growth: 4.2

Quality: 3.6

Yield: 0.0

Momentum: 4.5

Volatility: 0.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

15.7$

Current Price

15.71$

Potential

-0.00%

Expected Cash-Flows